These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30834564)

  • 1. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
    Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S
    Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
    Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
    Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
    Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
    Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
    Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
    Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
    Friedberg JW; Unger JM; Burack WR; Gopal AK; Raju RN; Nademanee AP; Kaminski MS; Li H; Press OW; Miller TP; Fisher RI
    Br J Haematol; 2014 Aug; 166(3):382-9. PubMed ID: 24749780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
    Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
    Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
    Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
    Beltran BE; Paredes S; Castro D; Cotrina E; Sotomayor EM; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e551-e557. PubMed ID: 31320254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
    He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
    Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
    Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.